Soru

Zorluk: OrtaInfectious Diseases

An oncology clinic evaluates a patient undergoing induction chemotherapy for acute myeloid leukemia who developed chills and a high temperature earlier today. The patient reports generalized weakness but denies cough, dysuria, abdominal pain, or skin changes. Vital signs show a temperature of 38.7∘C38.7^\circ\text{C} (101.7∘F101.7^\circ\text{F}), blood pressure of 118/76 mmHg118/76\text{ mmHg}, heart rate of 105/min105/\text{min}, and respiratory rate of 16/min16/\text{min}. Physical examination is unremarkable, with clear lung fields and no induration or erythema at the central venous catheter site. Laboratory studies reveal a total leukocyte count of 800/mm3800/\text{mm}^3 with 10%10\% neutrophils and 5%5\% bands. After obtaining appropriate blood and urine cultures, which of the following is the most appropriate empiric pharmacotherapy?

  1. Intravenous cefepimeCevap
  2. B
    Intravenous cefepime and vancomycin
  3. C
    Intravenous ceftriaxone and azithromycin
  4. D
    Oral ciprofloxacin and amoxicillin-clavulanate
  5. E
    Intravenous fluconazole

Cevap

Intravenous cefepime
The correct answer provides monotherapy with an antipseudomonal beta-lactam. Neutropenic fever is an oncologic emergency defined by an Absolute Neutrophil Count (ANC) < 500/mm3500/\text{mm}^3 and a single temperature equivalent to ≥38.3∘C\geq 38.3^\circ\text{C} (101.0∘F101.0^\circ\text{F}) or ≥38.0∘C\geq 38.0^\circ\text{C} (100.4∘F100.4^\circ\text{F}) sustained for over 1 hour. This patient's ANC is 120/mm3120/\text{mm}^3. In high-risk patients (such as those with profound neutropenia from hematologic malignancies), prompt initiation of empiric bactericidal intravenous therapy covering Pseudomonas aeruginosa is mandated. Cefepime, piperacillin-tazobactam, and meropenem are the drugs of choice.

Adım Adım Çözüm

1
Calculate the Absolute Neutrophil Count (ANC).
ANC = Total WBC x (% neutrophils + % bands). ANC = 800×(0.10+0.05)=120/mm3800 \times (0.10 + 0.05) = 120/\text{mm}^3.
An ANC < 500/mm3500/\text{mm}^3 (or expected to decrease to < 500/mm3500/\text{mm}^3 in 48 hours) combined with a fever defines febrile neutropenia.
2
Stratify the patient's risk to determine the treatment setting and route.
The patient is undergoing induction chemotherapy for AML and has profound neutropenia, making her a high-risk patient.
High-risk febrile neutropenia requires admission and intravenous broad-spectrum antibiotics, whereas selected low-risk patients may be treated orally as outpatients.
3
Select the appropriate empiric antibiotic regimen.
Intravenous antipseudomonal beta-lactam monotherapy (e.g., cefepime, meropenem, or piperacillin-tazobactam) is selected.
The patient is hemodynamically stable without signs of catheter infection or pneumonia, so MRSA coverage (vancomycin) is not empirically required.

Anahtar Kavram

The initial management of high-risk febrile neutropenia requires prompt initiation of an intravenous antipseudomonal beta-lactam antibiotic.
Tahmini Süre:1m 15s
Bu soruyu puanla